Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EMA Begins Setting Up New Bodies To Tackle Medical Product Shortages

April Workshop To Be Held To Explain Agency's Expanded Role

Executive Summary

A new EU regulation has come into effect that gives the European Medicines Agency wider powers to monitor, prevent and manage shortages of drugs and medical devices in public health emergencies. A number of steering groups and other bodies and networks are being set up to put the new systems into action.

You may also be interested in...



The EU NIS 2 Directive Is Here. What Does It Mean For Medtech?

The EU Network and Information Security (NIS) Directive 2 entered into force this year, replacing the original NIS Directive. Cybersecurity is at the heart of NIS 2, and some of the new provisions are particularly important for the medtech and health sector.

MDR And IVDR – Similar Step Ups, Varying Commercial Impacts

Medtech Insight spoke to the CEOs of two companies that recently had very different experiences with the new European IVDR and MDR regulations to gauge their thoughts on any potential commercial impacts.

Industry & Regulators To Align Advice on COVID-19 Vaccine Updates

A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT145142

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel